Table 1.
Patient demographic and clinical characteristics
| Descriptive cohort (n = 103) | Correlative cohort (n = 66) | Anti-EGFR treated (n = 39) | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Age (years) | ||||||
| Median | 64 | 60 | 62 | |||
| Range | 38-88 | 38-81 | 38-77 | |||
| Smoking history | ||||||
| Never smokers | 63 | 61 | 40 | 60 | 27 | 69 |
| Former smokers | 8 | 8 | 5 | 8 | 4 | 10 |
| Current smokers | 32 | 31 | 21 | 32 | 8 | 21 |
| Stage | ||||||
| IIIB | 30 | 29 | 17 | 26 | 11 | 28 |
| IV | 73 | 71 | 49 | 74 | 28 | 72 |
| Number of sites of metastases | ||||||
| 1 | 16 | 16 | 18 | 27 | 9 | 23 |
| 2 | 25 | 24 | 26 | 39 | 13 | 33 |
| ≥3 | 62 | 60 | 22 | 34 | 17 | 44 |
| CNS metastases | ||||||
| Yes | 14 | 14 | 12 | 18 | 7 | 18 |
| No | 89 | 86 | 54 | 82 | 32 | 82 |
| Previous surgery on primary | ||||||
| Yes | 46 | 45 | 20 | 30 | 14 | 36 |
| No | 57 | 55 | 46 | 70 | 25 | 64 |
| Previous (neo-)adjuvant CT | ||||||
| Yes | 9 | 9 | 5 | 8 | 4 | 10 |
| No | 94 | 91 | 61 | 92 | 35 | 90 |
| Previous adjuvant RT | ||||||
| Yes | 4 | 4 | 2 | 4 | 3 | 8 |
| No | 99 | 96 | 63 | 96 | 36 | 92 |
| First-line CT regimen | ||||||
| Platinum + Paclitaxel | 10 | 10 | 10 | 15 | 5 | 13 |
| Platinum + Gemcitabine | 39 | 39 | 39 | 59 | 21 | 54 |
| Platinum + Pemetrexed | 13 | 13 | 13 | 20 | 6 | 15 |
| Cisplatin + Vinorelbine | 2 | 2 | 2 | 3 | 1 | 3 |
| Cisplatin-based triplet CT | 2 | 2 | 2 | 3 | 2 | 5 |
| Single-agent CT* | 26 | 26 | - | - | 4 | 10 |
| Best supportive care only | 8 | 8 | - | - | - | - |
| Anti-EGFR TKI treatment line | ||||||
| 2 | 28 | 27 | 24 | 36 | 27 | 69 |
| ≥3 | 12 | 12 | 9 | 14 | 12 | 31 |
Abbreviations: TKIs tyrosine-kinase inhibitors, ECOG Eastern Cooperative Oncology Group, CNS central nervous system, CT chemotherapy, RT radiotherapy. *Single agent platinum, gemcitabine, vinorelbine, pemetrexed.